7-Nitroindazole

Identification

Name
7-Nitroindazole
Accession Number
DB02207  (EXPT00314)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
UX0N37CMVH
CAS number
2942-42-9
Weight
Average: 163.1335
Monoisotopic: 163.038176419
Chemical Formula
C7H5N3O2
InChI Key
PQCAUHUKTBHUSA-UHFFFAOYSA-N
InChI
InChI=1S/C7H5N3O2/c11-10(12)6-3-1-2-5-4-8-9-7(5)6/h1-4H,(H,8,9)
IUPAC Name
7-nitro-2H-indazole
SMILES
O=N(=O)C1=CC=CC2=CNN=C12

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UNitric oxide synthase, endothelialNot AvailableHuman
UNitric oxide synthase, inducibleNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
Ajulemic acidThe risk or severity of adverse effects can be increased when Ajulemic acid is combined with 7-Nitroindazole.
CP-945598The risk or severity of adverse effects can be increased when CP-945598 is combined with 7-Nitroindazole.
GW842166The risk or severity of adverse effects can be increased when GW842166 is combined with 7-Nitroindazole.
IbipinabantThe risk or severity of adverse effects can be increased when Ibipinabant is combined with 7-Nitroindazole.
NabiximolsThe risk or severity of adverse effects can be increased when Nabiximols is combined with 7-Nitroindazole.
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with 7-Nitroindazole.
RimonabantThe risk or severity of adverse effects can be increased when Rimonabant is combined with 7-Nitroindazole.
SLV319The risk or severity of adverse effects can be increased when SLV319 is combined with 7-Nitroindazole.
SurinabantThe risk or severity of adverse effects can be increased when Surinabant is combined with 7-Nitroindazole.
WIN 55212-2The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with 7-Nitroindazole.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
1893
PubChem Substance
46504896
ChemSpider
1821
BindingDB
50209245
ChEMBL
CHEMBL247378
HET
7NI
Wikipedia
7-Nitroindazole
PDB Entries
1foj / 1m8e / 1m9k

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.23 mg/mLALOGPS
logP1.76ALOGPS
logP1.59ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)10.22ChemAxon
pKa (Strongest Basic)-0.39ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area74.5 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity43.15 m3·mol-1ChemAxon
Polarizability14.49 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9911
Blood Brain Barrier+0.9745
Caco-2 permeable+0.5178
P-glycoprotein substrateNon-substrate0.8679
P-glycoprotein inhibitor INon-inhibitor0.9266
P-glycoprotein inhibitor IINon-inhibitor0.8616
Renal organic cation transporterNon-inhibitor0.8509
CYP450 2C9 substrateNon-substrate0.8587
CYP450 2D6 substrateNon-substrate0.8483
CYP450 3A4 substrateNon-substrate0.5888
CYP450 1A2 substrateInhibitor0.9418
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.6791
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5437
Ames testAMES toxic0.9122
CarcinogenicityNon-carcinogens0.7306
BiodegradationNot ready biodegradable0.9943
Rat acute toxicity2.7679 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6238
hERG inhibition (predictor II)Non-inhibitor0.9213
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-6901000000-ccdad7ad5ae99193261b

Taxonomy

Description
This compound belongs to the class of organic compounds known as indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzopyrazoles
Sub Class
Indazoles
Direct Parent
Indazoles
Alternative Parents
Nitroaromatic compounds / Benzenoids / Pyrazoles / Heteroaromatic compounds / Propargyl-type 1,3-dipolar organic compounds / Organic oxoazanium compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic zwitterions
show 2 more
Substituents
Benzopyrazole / Indazole / Nitroaromatic compound / Benzenoid / Azole / Pyrazole / Heteroaromatic compound / C-nitro compound / Organic nitro compound / Organic oxoazanium
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induce...
Gene Name
NOS3
Uniprot ID
P29474
Uniprot Name
Nitric oxide synthase, endothelial
Molecular Weight
133287.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity ...
Gene Name
NOS2
Uniprot ID
P35228
Uniprot Name
Nitric oxide synthase, inducible
Molecular Weight
131116.3 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on November 02, 2018 05:13